A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

Chee Khoon Lee,Shalini Subramaniam,Antony Mersiades,Jenna Mitchell,Hannora Jurkovic,Mariya Walker,Loc Le,Chris Brown,Benjamin Solomon,Thomas John,Martin R. Stockler,Bin-Chi Liao,James Chih-Hsin Yang,Chao Hua Chiu

A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

2020

Chee Khoon Lee
Shalini Subramaniam
Antony Mersiades
Jenna Mitchell
Hannora Jurkovic
Mariya Walker
Loc Le
Chris Brown
Benjamin Solomon
Thomas John
Martin R. Stockler
Bin-Chi Liao
James Chih-Hsin Yang
Chao Hua Chiu

TPS9631Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have proven remarkably effective in the treatment of advanced EGFR mutant non-small cell lung cancer (NS...

Keywords:

non squamous
Durvalumab
Tremelimumab
EGFR Tyrosine Kinase Inhibitors
Chemotherapy
Pathology
Medicine
Mutant
Cancer research
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations